<DOC>
	<DOCNO>NCT00279084</DOCNO>
	<brief_summary>In type 2 diabetic , progression chronic kidney disease end stage renal disease may slow therapeutic intervention angiotensin convert enzyme inhibitor use , control high blood pressure proteinuria , control hyperglycaemia , protein intake restriction , smoke cessation . Correcting anaemia patient may prevent impairment renal function . International guideline indicate haemoglobin level 110 g/L patient . We conduct interventional randomize trial evaluate potential benefit haemoglobin level 130 g/L patient type 2 diabetes chronic kidney disease define Cockcroft 's creatinine clearance 25 - 60 ml/min .</brief_summary>
	<brief_title>NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect Two Haemoglobin Levels</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Type 2 diabetes . Age 18 80 year , male female . Cockcroft 's clearance 25 60 ml / min . Haemoglobin level superior 100 g/L strictly inferior 130 g/L Malignancy Solid organ transplant Acute pathology two month inclusion date Myocardial infarction , stroke , pulmonary embolism six month inclusion date Contraindication martial treatment EPO treatment Present inclusion another clinical study Patient answer question SF36 questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Anaemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Randomized trial</keyword>
</DOC>